As if it were not challenging enough during the “normal emergencies” [1] of the United States-led War on Drugs, research and advocacy for sane drug policies becomes even more complicated during a global pandemic.

COVID-19 has exposed the deep and enduring health and social inequities that mark our biopolitical moment, and the punitive ways that we govern people who use …